Correlation between histological type and immunohistochemical profile of prostate cancer and gleason scale gradation

Experimental Oncology

Volumn 31, Issue 4, 2009, Pages 246-249

  Iemelynova, A A ^a   Grygorenko, V M ^a   Cheremuha, S V ^a   Romanenko, A M ^a  

^a STATE INSTITUTION NATIONAL RESEARCH CENTER FOR RADIATION MEDICINE OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE   (Ukraine)

Author keywords

Bcl 2; Biopsy specimens; Gleason scale; p53 and Ki 67 proteins; PIN and PIA locus; Prostate cancer

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; KI 67 ANTIGEN; PARAFFIN; PROTEIN BCL 2; PROTEIN P53;

ACINAR CELL CARCINOMA; ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; GLEASON SCORE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MORPHOGENESIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; TUMOR CELL;

ADENOCARCINOMA; APOPTOSIS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; PRECANCEROUS CONDITIONS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 75149150327     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Ferlay J, Aitier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-92.
2. Fedorenko ZP, Goulak LO, Gorokh EL, et al. Bulletin of National Cancer Registry of Ukraine 2007-2008. Kiev: National Institute of Cancer 2009; 10: 104 p.
3. Fedorenko ZP, Gulak LO, Goroh EL, et al. Cancer in Ukraine 2006-2007. The morbidity, mortality, the data on oncological service activity. Bulletin National Cancer-register 2008; 9: 47-8. (In Ukrainian).
4. Gerber GS, Thompson IM, Thisted R, et al. Disease specific survival following routine prostate cancer screening by digital rectal examination. JAMA 1993; 269: 61-4.
5. Vorobyev AV, Male screening, standard examination of patients, prostate cancer classification. Pract Oncol 2001; 2: 8-16.
6. Huland H. Radical prostatectomy: options and issues. Eur Urol 2001; 39: 3-9.
7. Greenlee RT, Hill-Harmon M-B, Murray T, et al. Cancer statistics 2001. Cancer J Clin 2001; 51: 15-36.
8. Chumak PM. p53 protein and its universal functions in cellular organism. Adv Biol Chem 2007; 47: 3-52 (in Russian).
9. Bauer JJ, Sesterhenn IA, Mostofi KF, et al. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Cancer Res 1995; 1: 1295-300.
10. Povelica EA, Sukonko OG, Rolevich AI. Molecular-biological markers of prostate cancer (review). http://www.uroweb.ru/ news/955.html (in Russian).
11. McDonnell TJ, Chari NS, Cho-Vega JH, et al. Biomarker expression patterns that correlate with high grade features in treatment naive, organ-confined prostate cancer. BMC Med Genomics 2008; 1: 1.
12. ink4a and p53 as marker of oncogenic transformation and probability of progression of cervical intraperitoneal neoplasms. Morphology 2007; 1: 45-55 (in Ukrainian).
13. Shaceva TA, Muhina MS. Ki-67 antigen in evaluation of tumor proliferation: structure and functions. Voprosy Oncologii 2004; 50: 157-64 (in Russian).
14. Bostwick DG, Qian J. High-grade prostatic intraepithelial neoplasia. Mod Pathol 2004; 17: 360-79.